MARKET

ABIO

ABIO

Arca Biopharma Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.370
+0.071
+3.09%
Closed 17:14 05/25 EDT
OPEN
2.250
PREV CLOSE
2.299
HIGH
2.410
LOW
2.250
VOLUME
137.48K
TURNOVER
--
52 WEEK HIGH
3.900
52 WEEK LOW
1.710
MARKET CAP
34.15M
P/E (TTM)
-1.8468
1D
5D
1M
3M
1Y
5Y
ARCA biopharma Retains Ladenburg Thalmann to Support Strategic Options Review
WESTMINSTER, Colo., May 05, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO) today announced that it has retained Ladenburg Thalmann & Co. Inc. to act as its financial advisor. In April 2022, the Board of Directors established a Special Committ...
GlobeNewswire · 05/05 20:15
ARCA biopharma GAAP EPS of -$0.23
ARCA biopharma press release (NASDAQ:ABIO): Q1 GAAP EPS of -$0.23. Cash and cash equivalents were $49.1 million as of March 31, 2022, compared to $53.4 million as of December 31,
Seekingalpha · 05/02 20:57
BRIEF-Arca Biopharma Announces First Quarter 2022 Financial Results
reuters.com · 05/02 20:53
-- Earnings Flash (ABIO) ARCA BIOPHARMA Reports Q1 Loss $-0.23
MT Newswires · 05/02 16:26
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Rockwell Medical (NASDAQ:RMTI) stock rose 9.2% to $0.4 during Monday's after-market session. The company's market cap stands at $37.5 million.
Benzinga · 04/18 21:34
BRIEF-Arca Biopharma Establishes Special Committee Of The Board Of Directors
reuters.com · 04/18 20:50
ARCA biopharma establishes special board committee to evaluate strategic options
ARCA biopharma (NASDAQ:ABIO) on Monday established a special committee of its board of directors to evaluate strategic options for the biopharmaceutical company. ABIO did not specify what kind of options
Seekingalpha · 04/18 20:44
ARCA biopharma Reports Has Established Special Committee Of Board
ARCA biopharma, Inc. (NASDAQ:ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced that its Board of Directors
Benzinga · 04/18 20:31
More
No Data
Learn about the latest financial forecast of ABIO. Analyze the recent business situations of Arca Biopharma Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average ABIO stock price target is 7.00 with a high estimate of 7.00 and a low estimate of 7.00.
High7.00
Average7.00
Low7.00
Current 2.370
EPS
Actual
Estimate
-0.31-0.23-0.16-0.08
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Institutional Holdings
Institutions: 30
Institutional Holdings: 1.27M
% Owned: 8.80%
Shares Outstanding: 14.41M
TypeInstitutionsShares
Increased
5
70.68K
New
5
65.61K
Decreased
6
34.09K
Sold Out
4
89.94K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.55%
Pharmaceuticals & Medical Research
+0.02%
Key Executives
Non-Executive Chairman/Independent Director
Robert Conway
Chief Executive Officer/President/Director
Michael Bristow
Chief Financial Officer/Chief Accounting Officer
C. Jeffrey Dekker
Chief Operating Officer
Thomas Keuer
Senior Vice President/General Counsel/Secretary
Christopher Ozeroff
Vice President
Christopher Graybill
Independent Director
Linda Grais
Independent Director
Anders Hove
Independent Director
Daniel Mitchell
Independent Director
Raymond Woosley
No Data
No Data
About ABIO
ARCA biopharma, Inc. (ARCA) is a biopharmaceutical company. The Company is focused on development and commercialization of targeted therapies for cardiovascular diseases. The Company's lead product includes Recombinant Nematode Anticoagulant Protein c2, or rNAPc2 (AB201) and Gencaro(bucindolol hydrochloride). rNAPc2 (AB201) is a treatment for diseases caused by ribonucleic acid (RNA), viruses, focusing on COVID-19, the disease syndrome caused by the SARS-CoV-2 virus. Gencaro(bucindolol hydrochloride) is a pharmacogenetically-targeted beta-adrenergic receptor antagonist with mild vasodilator properties for the treatment of atrial fibrillation (AF) in patients with heart failure. AF is the form of cardiac arrhythmia, a disruption of the heart’s normal rhythm or rate. The Company is conducting Phase II b clinical trial of rNAPc2 (AB201), ASPEN-COVID-19. It is also conducting Phase IIB/III clinical trial of Gencaro.

Webull offers kinds of Arca Biopharma Inc stock information, including NASDAQ:ABIO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ABIO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ABIO stock methods without spending real money on the virtual paper trading platform.